Why the study?
Do TAVI recipients achieve a life expectancy comparable to their age- and sex-matched controls in the general population?
Do TAVI recipients achieve a life expectancy comparable to their age- and sex-matched controls in the general population?
Answers are grounded in this paper and cite their sources.
This editorial discusses whether TAVI recipients achieve a life expectancy comparable to the general population, which is critical for guiding patient selection and resource allocation.
This invited editorial refers to ‘Long-term survival after transcatheter aortic valve implantation in the modern era compared with the general population—a nationwide Danish cohort study’, by M.S. Reinert et al., https://doi.org/10.1093/ehjqcco/qcaf061. Transcatheter aortic valve implantation (TAVI) was initially introduced as a treatment for patients with severe aortic stenosis (AS) deemed inoperable or at prohibitive risk for surgical aortic valve replacement. Over the past two decades, the rapid evolution of TAVI has transformed the treatment of severe AS, broadening indications and enabling its use in younger patients and those at low- to intermediate-surgical risk.1,2 As TAVI continues to emerge as the preferred treatment for many patients with severe AS, particularly among elderly patients, an important question remains: do TAVI recipients achieve a life expectancy comparable to their age- and sex-matched controls in the general population? This question holds significant importance in guiding patient selection criteria and optimising healthcare resource allocation, especially as the TAVI population becomes younger and more heterogeneous.
No takes yet. Share an insight, caveat, or question.
Sina Kazemian (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: